Welcome to Mergermarket's Annual Life Sciences and Healthcare M&A Forum
Within the life sciences industry, market observers are expecting biotechnology firms to be a standout performer in M&A over the next 12 months. The subsector accounted for 43% of life sciences activity in 2016, although the subsector jumped to 46% in 1H17. Wall St is anticipating investment and M&A to grow over the next several quarters driven by low interest rates, balance sheet cash and the need for larger firms to continue developing blockbuster drugs to fuel revenue growth.
There remains uncertainty around health insurance and hospital M&A, which the latter saw many regional and chain operators merge with one another or with physician groups, digital health firms and service providers. Similarly, health firms of all sizes have sought out acquisitions of digital health companies that provide a range of services from data and analytics to healthcare IT partly because of the move to value-based care over fee-for-a-service.
This event will feature esteemed panelists as they discuss the latest issues and trends that are impacting deal activity and financing in the healthcare and life sciences industries.